These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 29133707)

  • 1. Impact of transsphenoidal surgery on asymptomatic cardiomyopathy in patients with acromegaly. A single-blinded study.
    Srinivasan A; Bahl A; Bhagat H; Dutta P; Rai A; Devgun JS; Kaur R; Mukherjee KK
    Neurol India; 2017; 65(6):1312-1316. PubMed ID: 29133707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure?
    Damjanovic SS; Neskovic AN; Petakov MS; Popovic V; Macut D; Vukojevic P; Joksimovic MM
    Clin Endocrinol (Oxf); 2005 Apr; 62(4):410-7. PubMed ID: 15807870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of successful transsphenoidal surgery on cardiovascular risk factors in acromegaly.
    Jaffrain-Rea ML; Minniti G; Moroni C; Esposito V; Ferretti E; Santoro A; Infusino T; Tamburrano G; Cantore G; Cassone R
    Eur J Endocrinol; 2003 Feb; 148(2):193-201. PubMed ID: 12590638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth hormone status predicts left ventricular mass in patients after cure of acromegaly.
    Wexler TL; Durst R; McCarty D; Picard MH; Gunnell L; Omer Z; Fazeli P; Miller KK; Klibanski A
    Growth Horm IGF Res; 2010 Oct; 20(5):333-7. PubMed ID: 20598930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly.
    Colao A; Cuocolo A; Marzullo P; Nicolai E; Ferone D; Florimonte L; Salvatore M; Lombardi G
    J Clin Endocrinol Metab; 1999 Jan; 84(1):17-23. PubMed ID: 9920056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels.
    Feelders RA; Bidlingmaier M; Strasburger CJ; Janssen JA; Uitterlinden P; Hofland LJ; Lamberts SW; van der Lely AJ; de Herder WW
    J Clin Endocrinol Metab; 2005 Dec; 90(12):6480-9. PubMed ID: 16159936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of acromegaly treatment on left ventricular systolic function assessed by speckle tracking echocardiography in relation to sex differences: results from a prospective single center study.
    Popielarz-Grygalewicz A; Stelmachowska-Banaś M; Raczkiewicz D; Czajka-Oraniec I; Zieliński G; Kochman W; Dąbrowski M; Zgliczyński W
    Front Endocrinol (Lausanne); 2023; 14():1154615. PubMed ID: 37223021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance.
    Pivonello R; Galderisi M; Auriemma RS; De Martino MC; Galdiero M; Ciccarelli A; D'Errico A; Kourides I; Burman P; Lombardi G; Colao A
    J Clin Endocrinol Metab; 2007 Feb; 92(2):476-82. PubMed ID: 17105844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changing patterns of insulin-like growth factor-I and glucose-suppressed growth hormone levels after pituitary surgery in patients with acromegaly.
    Espinosa-de-los-Monteros AL; Mercado M; Sosa E; Lizama O; Guinto G; Lopez-Felix B; Garcia O; Hernández I; Ovalle A; Mendoza V
    J Neurosurg; 2002 Aug; 97(2):287-92. PubMed ID: 12186455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly.
    Colao A; Marzullo P; Ferone D; Spinelli L; Cuocolo A; Bonaduce D; Salvatore M; Boerlin V; Lancranjan I; Lombardi G
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3132-40. PubMed ID: 10999798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy.
    Colao A; Baldelli R; Marzullo P; Ferretti E; Ferone D; Gargiulo P; Petretta M; Tamburrano G; Lombardi G; Liuzzi A
    J Clin Endocrinol Metab; 2000 Jan; 85(1):193-9. PubMed ID: 10634386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin-like growth factor binding protein-3 levels during early and late follow-up after surgery in acromegalic patients.
    Charalampaki P; Hildebrandt G; Schaeffer HJ; Schönau E; Klug N
    Exp Clin Endocrinol Diabetes; 1998; 106(2):130-4. PubMed ID: 9628244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of acromegaly by endoscopic transsphenoidal surgery: surgical experience in 214 cases and cure rates according to current consensus criteria.
    Hazer DB; Işık S; Berker D; Güler S; Gürlek A; Yücel T; Berker M
    J Neurosurg; 2013 Dec; 119(6):1467-77. PubMed ID: 24074496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Marked improvement in cardiovascular function after successful transsphenoidal surgery in acromegalic patients.
    Minniti G; Moroni C; Jaffrain-Rea ML; Esposito V; Santoro A; Affricano C; Cantore G; Tamburrano G; Cassone R
    Clin Endocrinol (Oxf); 2001 Sep; 55(3):307-13. PubMed ID: 11589673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly.
    Serri O; Beauregard C; Hardy J
    J Clin Endocrinol Metab; 2004 Feb; 89(2):658-61. PubMed ID: 14764777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Body mass index and insulin-like growth factor 1 as risk factors for discordant growth hormone and insulin-like growth factor 1 levels following pituitary surgery in acromegaly.
    Zhang S; Li Y; Guo X; Gao L; Lian W; Yao Y; Feng M; Bao X; Wang R; Xing B
    J Formos Med Assoc; 2018 Jan; 117(1):34-41. PubMed ID: 28341329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can immediate postoperative random growth hormone levels predict long-term cure in patients with acromegaly?
    Dutta P; Korbonits M; Sachdeva N; Gupta P; Srinivasan A; Devgun JS; Bajaj A; Mukherjee KK
    Neurol India; 2016; 64(2):252-8. PubMed ID: 26954802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Lowered ghrelin levels in acromegaly—normalization after treatment].
    Kozakowski J; Rabijewski M; Zgliczyński W
    Endokrynol Pol; 2005; 56(6):862-70. PubMed ID: 16821203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of somatostatin analogues on acromegalic cardiomyopathy: results from a prospective study using cardiac magnetic resonance.
    Bogazzi F; Lombardi M; Strata E; Aquaro G; Lombardi M; Urbani C; Di Bello V; Cosci C; Sardella C; Talini E; Martino E
    J Endocrinol Invest; 2010 Feb; 33(2):103-8. PubMed ID: 20348836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac effect of thyrotoxicosis in acromegaly.
    Marzullo P; Cuocolo A; Ferone D; Pivonello R; Salvatore M; Lombardi G; Colao A
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1426-32. PubMed ID: 10770177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.